A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma

Inclusion Criteria:

- M or F 18 or older with histologically confirmed metastatic (Stage IV) melanoma of
cutaneous origin

- ECOG performance status of greater than or equal to 2

- Measurable disease per RECIST criteria

- Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy
regimens are allowed)

- At least 4 weeks have passed since last chemotherapy or immunotherapy

- At least 2 weeks have passed since last radiotherapy.

- Life expectancy of greater than 12 weeks

- Clinical lab values within protocol parameters

Exclusion Criteria:

- Female patients pregnant or lactating

- Female patients of childbearing potential not using or not willing to use effective
contraception

- Presence of a second malignancy other than nonmelanoma skin cancer

- Presence of a clinically significant and uncontrolled infection

- Presence of clinically significant arrythmias

- Presence of serious concurrent illness or other conditions that do not permit
adequate follow-up and compliance with protocol

- History of severe hypersensitivity reactions to taxanes

- Use of any investigational agents within 4 weeks prior to the first dose of study
drug